Previous Close | 8.82 |
Open | 8.95 |
Bid | 8.67 x 1000 |
Ask | 9.42 x 800 |
Day's Range | 8.86 - 9.34 |
52 Week Range | 5.76 - 10.80 |
Volume | |
Avg. Volume | 371,491 |
Market Cap | 620.918M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | 2.75 |
EPS (TTM) | 3.23 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.02 |
Subscribe to Yahoo Finance Plus to view Fair Value for ZYME
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on January 8-11, 2024 and a corporate presentation on January 11th, 2024 at 8:15 am Pacific Time. The presentation and web
Net loss for the first nine months of 2023 decreased by 44% as compared to the same period in 2022Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyondUpdated clinical results from Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) presented by our partner BeiGene at the European Socie
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on November 14th at 11:30 am Greenwich Mean Time in London, UK.Stifel 2023 Healthcare Conference: